CareDx Lifts 2026 Profit Outlook To $90 Million-$100 Million After Revenue Jumps 39%

The transplant-testing company also raised its 2026 revenue forecast to $520 million to $530 million on third-quarter sales of $139 million.

Share
CareDx Lifts 2026 Profit Outlook To $90 Million-$100 Million After Revenue Jumps 39%

CareDx, which sells blood tests that check transplant recipients for signs of organ injury or rejection, raised its 2026 outlook on Thursday after third-quarter revenue jumped 39% to $139 million. Adjusted EBITDA, the company's adjusted profit measure, is now expected at $90 million to $100 million for the year, up from $66 million to $78 million.

Testing drives the quarter

Revenue was $139 million against $100 million a year earlier, driven mainly by Testing Services and Patient and Digital Solutions, the company said. Testing Services revenue rose 65% to $119 million, including $12 million from Specialty Oncology and $15 million for tests performed in prior periods, versus $6 million a year earlier.

Excluding that prior-period revenue, Testing Services grew approximately 58%. Volume was approximately 75,900 tests, up 51%, including contributions from Specialty Oncology. Patient and Digital Solutions revenue rose 31% to $20 million, led by CareDx Pharmacy services.

The quarter does not include Lab Products revenue, because CareDx completed the sale of that business on June 30, 2026.

Profit climbs, helped by a tax benefit

Net income was $19 million, or $0.35 per diluted share, compared with $2 million, or $0.03 per share, a year earlier. An $8.6 million income tax benefit contributed to the result; income from operations was $8.1 million, against a small loss a year earlier.

Adjusted EBITDA reached $30 million, versus $15 million in the third quarter of 2025, a margin of about 22% against about 15%. CareDx attributed the gain to revenue growth, higher gross profit and disciplined spending. Operating cash flow was $13 million.

For the full year, revenue guidance rises to $520 million to $530 million from $490 million to $500 million.

CareDx closed its acquisition of Naveris on July 1, 2026, paying $160 million in cash with up to $100 million more in contingent consideration. That brought in the NavDx cancer test and the Specialty Oncology revenue.

Cash and cash equivalents stood at $250.5 million on September 30, up from $65.4 million at the end of 2025.

CEO John Hanna said the company sees "significant clinical interest in how molecular information can inform more decisions across a patient's care journey." CareDx is targeting a first-quarter 2027 commercial launch for AlloHeme and broader availability of HistoMap Kidney in 2027, with both aiming for lab-certification readiness before year-end.

CareDx is aiming for a first-quarter 2027 launch of AlloHeme, its next planned commercial product.

Sources

More on CareDx

All CareDx (CDNA) coverage →